



July 28, 2020

To,

Manager (CDR)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, Dalal Street,
Mumbai-400001.

Ref: DR LALCHANDANI LABS LIMITED (Scrip Code: 541299)

Subject: Outcome of the Board Meeting dated 28.07.2020.

Dear Sir/ Madam,

With reference to the above cited subject, we would like to inform you that Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 we are enclosing herewith;

1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March, 2020 along with Auditors Report on Audited Financial Results is also enclosed herewith, and
2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May, 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March, 2020.
3. Appointment of M/s Heena Taneja and Associates, Company Secretaries, as a Secretarial Auditor and Scrutinizer for the Financial Year 2019-2020.

The Said meeting of the Board of Directors commenced at 04.00.pm and concluded at 7.30 pm.

Please take the same on your record.

Thanking You,

Yours Faithfully,

For DR LALCHANDANI LABS LIMITED



Arjan Lalchandani
Managing Director
DIN: 07014579

Encl: As Above



DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2020*Amount Rs. in Lacs*

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2020	30.09.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un-audited	Audited	Audited	Audited
I	Revenue from Operations	306.96	303.43	264.14	610.39	526.10
II	Other Income		-	0.57	-	0.57
III	Total Revenue (I+II)	306.96	303.43	264.71	610.39	526.67
IV	Expenses					
	(a) Cost of materials consumed	63.42	51.20	21.60	114.62	60.57
	(b) Purchases of stock in trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work in progress and stock in trade	-	-	-	-	-
	(d) Employee benefits expense	41.94	44.27	43.05	86.21	94.59
	(e) Finance Cost	9.29	9.21	4.59	18.50	13.63
	(f) Depreciation and amortisation expense	21.76	20.54	19.67	42.30	34.89
	(g) Other Expenses	147.58	135.10	130.27	282.68	251.09
	Total Expenses	283.99	260.32	219.18	544.30	454.77
V	Profit before exceptional and extraordinary items and tax (III - IV)	22.97	43.11	45.53	66.08	71.90
VI	Exceptional Items					
VII	Profit extraordinary items and tax (V - VI)	22.97	43.11	45.53	66.08	71.90
VIII	Extraordinary Items					
IX	Profit before tax (VIII - IX)	22.97	43.11	45.53	66.08	71.90
X	Tax Expenses :					
	(1) Current Tax	15.81	-	8.92	15.81	15.77
	(2) Deferred Tax	2.84	-	2.78	2.84	2.78
XI	Profit / (Loss) from Period from continuing operations (IX-X)	4.32	43.11	33.84	47.43	53.35
XII	Profit (Loss) from discontinuing Operations					
XIII	Tax Expense of Discontinuing operations					
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)				-	-
XV	Profit (Loss) for the period (XI +XIV)	4.32	43.11	33.84	47.43	53.35
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	0.10	0.99	0.78	1.09	1.23

(b) Diluted (Rs.)	0.10	0.99	0.78	1.09	1.23
-------------------	------	------	------	------	------

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on July 28, 2020.
2. There were no investor complaints received / pending as at 31st March, 2020
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.

For Dr Lalchandani Labs Limited,



(Dr. Arjan Lalchandani)

Managing Director (DIN: 07014579)

New Delhi

28-Jul-20

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

STANDALONE STATEMENT OF ASSETS AND LIABILITIES THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2020*Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	
		31.03.2020	31.03.2019
1	Shareholders' Funds		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	420.76	373.33
	(c) Money received against share warrants		
	Sub-total-Shareholders' Funds	854.07	806.64
2	Share application money pending allotment		
3	Non Current Liabilities		
	(a) Long Term Borrowings	170.85	85.46
	(b) Deferred Tax Liability	8.01	5.17
	(c) Other Long Term Liabilities		
	(d) Long Term Provisions		
	Sub-total-Non Current Liabilities	178.86	90.62
4	Current Liabilities		
	(a) Short Term Borrowings	5.01	5.00
	(b) Trade Payables	112.36	64.60
	(c) Other Current Liabilities	27.31	28.10
	(d) Short Term Provisions	15.81	15.77
	Sub-total-Current Liabilities	160.49	113.47
	TOTAL EQUITY AND LIABILITIES	1,193.42	1,010.74
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	331.63	312.12
	(ii) Intangible assets	15.49	15.91
	(b) Non Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	31.75	31.75
	(d) Other Non Current Assets	34.30	45.74
	Sub-total-Non Current Assets	437.26	429.61
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	49.70	39.21
	(c) Trade Receivables	332.75	180.70
	(d) Cash & cash equivalents	225.28	202.40

(e) Short Term Loans & Advances	106.17	105.24
(f) Other Current Assets	42.26	53.57
Sub-total-Current Assets	756.16	581.13
TOTAL ASSETS	1,193.42	1,010.74

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
(Managing Director DIN: 07014579)

New Delhi

28-Jul-20

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

Cash Flow Statement for the Year Ended 31.03.2020

	<u>Particulars</u>	<u>Amount</u> (in Rs. Lacs)
A	<u>Cash Flow From Operating Activities</u>	
	Net Profit/(Loss) Before Tax	66.08
	Adjustment For:	
	Depreciation	42.30
	Interest Expense	9.15
	<u>Operating Profit Before Working Capital Changes</u>	<u>117.54</u>
	<u>Changes in Working Capital</u>	
	Change in Sundry Debtors	(152.05)
	Change in Other Current Assets & Non Current Assets	22.75
	Change in Trade Payables	47.76
	Changes in Inventories	(10.50)
	Change in Other Current Liabilities	(0.79)
	Direct Taxes Paid	(15.77)
	<u>Net Cash Flows From Operating Activities(A)</u>	<u>(108.59)</u>
B	<u>Cash Flow From Investing Activities</u>	
	Purchase of Fixed Assets	(61.39)
	Loans and Advances given	(0.93)
	<u>Net Cash Flow From Investing Activities (B)</u>	<u>(62.32)</u>
C	<u>Cash Flow From Financing Activities</u>	
	Long Term Borrowings taken	85.40
	Interest Paid	(9.15)
	<u>Net Cash Flow From Financing Activities (C)</u>	<u>76.25</u>
	<u>Net Change in Cash (A+B+C)</u>	<u>22.88</u>
	Cash and Cash Equivalents at the Beginning of Year	<u>202.40</u>
	Cash and Cash Equivalents at the End of Year	<u><u>225.28</u></u>

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
(Managing Director DIN: 07014579)

New Delhi
28-Jul-20



Jain Agarwal & Company

Chartered Accountants

TO

**THE BOARD OF DIRECTORS OF
DR LALCHANDANI LABS LIMITED**

We have audited the yearly Financial Results of Dr Lalchandani Labs Limited for the year ended 31st March, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These Financial Results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Covid-19 has put significant accounting and auditing challenges due to the Government's restrictions imposed during the lockdown for safety concerns. We have performed alternate audit procedures based on documents and information made available and relied upon by us.

Covid Impact - In view of the highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent of the circumstances, as they evolve.

Our conclusion is not modified in respect of this matter.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the year ended 31st March, 2020.

For Jain Agarwal and Company

Chartered Accountants

FRN.: 024866N

New Delhi

CA Karan Jain

(Partner)

M.No.: 521992

UDIN: 20521992AAAAAS8083

Place: New Delhi

Date: 28th July, 2020



Date: July 28, 2020

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Ref: Dr Lalchandani Labs Limited (Scrip Code – 541299)

Subject- Declaration of Audit Report with Unmodified Opinion pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir/ Madam,

We hereby declare that Jain Agarwal and Company, Chartered Accountant (Firm's Registration No. 024866N), Statutory Auditors of the Company, have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2020.

The declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/ LAD-NRO/GN/2016-17/001 dated May 25, 2016 and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

This is for your information and records.

Thanking you,

For **Dr Lalchandani Labs Limited**



Arjan Lalchandani
Managing Director
DIN: 07014579

Encl: As Above





Date: July 28, 2020

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Ref: Dr Lalchandani Labs Limited (Scrip Code – 541299)

Subject- Disclosure on the Impact of COVID-19 Pandemic.

Dear Sir/ Madam,

On March 11, 2020, the World Health Organization declared Covid-19 outbreak as a pandemic. Responding to the potentially serious threat that this pandemic has to public health, the Indian Government has taken a series of measures to contain the outbreak, which included imposing multiple 'lock-downs' across the country, from March 22, 2020, and extended up to May 31, 2020. The lockdowns and restrictions imposed on various activities due to COVID — 19 pandemic have posed challenges to all the businesses of Dr Lalchandani Labs Limited (the "Company").

Lockdown guidelines issued by Central / State governments mandated closure of the operations and other forms of public transport. This has resulted in temporary shutdowns of our operation. With the lifting of the partial lockdown restrictions, the Company has started the operation as per the government prescribed guidelines, after establishing thorough and well rehearsed safety protocols.

The Company expects the demand for its services to pick up albeit at a slower pace once lockdown is lifted and recovery in business. The Company has assessed the potential impact of Covid-19 on its capital and financial resources, profitability, liquidity position, ability to service debt and other financing arrangements, supply chain and demand for its services. Various steps have been initiated to raise finances from banks and institutions for working capital needs and the Company is in a comfortable liquidity position to meet its commitments. The Company has also assessed the potential impact of Covid-19 on the carrying value of property, plant & equipment, right of use assets, intangible assets, investments, trade receivables, inventories, and other current assets appearing in the financial statements of the Company. In developing the assumptions and estimates relating to the future uncertainties in the economic conditions because of this pandemic, the Company as at the date of approval of these Financial statements has used internal and external sources of information and based on current estimates, expects to recover the carrying amounts of these assets.





The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial statements and the Company will continue to closely monitor any material changes to future economic conditions.

This is for your information and records.

Thanking you,

For **Dr Lalchandani Labs Limited**



Arjan Lalchandani
Managing Director
DIN: 07014579

